search
Back to results

The Clinical Effect of MK0476 With Concomitant Administration of and Removal of Inhaled Beclomethasone in Asthmatic Patients (0476-029)

Primary Purpose

Asthma

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
montelukast sodium
beclomethasone
Placebo inhaler
placebo tablet
Sponsored by
Organon and Co
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma focused on measuring chronic asthma

Eligibility Criteria

15 Years - 85 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Female patients tested negative for pregnancy and agreed to use appropriate contraceptives through out the study
  • Patient was a nonsmoker
  • Patient was in good general health (except for asthma)

Exclusion Criteria:

  • Patient was hospitalized
  • Patient was female who was less than 8 weeks postpartum or breast feeding
  • Patient planned to move or vacation away during the study
  • Patient had major surgery within 4 weeks the past 4 weeks
  • Patient has donated blood or participated in a clinical trial within the past 4 weeks
  • Patient was a regular user or recent abuser of alcohol or illicit drugs
  • Patient was 40% over or under normal weight for height

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm Type

    Experimental

    Experimental

    Experimental

    Placebo Comparator

    Arm Label

    1

    2

    3

    4

    Arm Description

    Montelukast + Beclomethasone

    Montelukast + Placebo inhaler

    Placebo tablet + Beclomethasone

    Placebo tablet + Placebo inhaler

    Outcomes

    Primary Outcome Measures

    Mean Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) in Patients With Chronic Asthma
    Mean percent change from baseline in FEV1 in patients with chronic asthma averaged over 16 weeks for the Beclo and MK+ Beclo groups and averaged over last 10 weeks for the Placebo and MK groups
    Mean Change From Baseline in Daytime Symptom Score on the Daytime Asthma Symptoms Diary in Patients With Chronic Asthma
    The daily daytime symptom score was determined by averaging the daily scores (the patient scored his/her symptoms [from 0 (best) to 6 (worst)] on a daily basis.) for the four questions on the Daytime Asthma Symptoms Diary. The average daytime symptom score for the visit was determined by averaging the daily symptom scores over all days between two consecutive visits.

    Secondary Outcome Measures

    Mean Percent Change From Baseline in Total Daily Beta-agonist Medication Use
    Beta-agonist medication use from the daytime and overnight asthma symptoms diaries for each 24-hour period was added to determine the daily total number of puffs used. The average daily number of puffs for the visit was determined as the average daily number of puffs over all days between consecutive visits.
    Mean Change From Baseline in Morning Peak Flow Rate (PEFR) in Patients With Chronic Asthma
    Morning PEFR was measured in triplicate immediately upon arising before taking any medication and the best value recorded on the overnight asthma symptoms diary. The mean morning PEFR for the visit was determined by averaging all valid PEFR measurements for the days between consecutive visits.
    Mean Change From Baseline in Nocturnal Asthma Score on the Overnight Asthma Symptoms Diary in Nocturnal Asthmatic Patients Only
    Mean change from baseline in Nocturnal asthma score; the patient scored his/her symptoms [from 0 (best) to 3 (worst)] on a daily basis. Responses to the question, "Did you wake up with asthma symptoms?" (no, once, more than once, awake "all night"), were assigned numerical values (0, 1, 2, 3, respectively). The average score for the visit was determined by averaging the daily scores over all days between consecutive visits.

    Full Information

    First Posted
    May 29, 2009
    Last Updated
    February 1, 2022
    Sponsor
    Organon and Co
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00911547
    Brief Title
    The Clinical Effect of MK0476 With Concomitant Administration of and Removal of Inhaled Beclomethasone in Asthmatic Patients (0476-029)
    Official Title
    A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 2-Period, Parallel-Group Study to Assess the Clinical Effect of MK0476 With Concomitant Administration of and Removal of Inhaled Beclomethasone in Asthmatic Patients
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2022
    Overall Recruitment Status
    Completed
    Study Start Date
    March 1995 (undefined)
    Primary Completion Date
    April 1996 (Actual)
    Study Completion Date
    May 1996 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Organon and Co

    4. Oversight

    5. Study Description

    Brief Summary
    This study will investigate the additive effect of montelukast (MK0476) taken along with inhaled beclomethasone versus inhaled beclomethasone alone.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Asthma
    Keywords
    chronic asthma

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigator
    Allocation
    Randomized
    Enrollment
    642 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    1
    Arm Type
    Experimental
    Arm Description
    Montelukast + Beclomethasone
    Arm Title
    2
    Arm Type
    Experimental
    Arm Description
    Montelukast + Placebo inhaler
    Arm Title
    3
    Arm Type
    Experimental
    Arm Description
    Placebo tablet + Beclomethasone
    Arm Title
    4
    Arm Type
    Placebo Comparator
    Arm Description
    Placebo tablet + Placebo inhaler
    Intervention Type
    Drug
    Intervention Name(s)
    montelukast sodium
    Other Intervention Name(s)
    MK0476
    Intervention Description
    10 mg tablet taken once daily at bedtime for 16 weeks
    Intervention Type
    Drug
    Intervention Name(s)
    beclomethasone
    Intervention Description
    200 ug inhaled, taken twice daily for 16 weeks
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo inhaler
    Intervention Description
    placebo inhaler taken twice daily for 16 weeks
    Intervention Type
    Drug
    Intervention Name(s)
    placebo tablet
    Intervention Description
    placebo tablet taken once daily at bedtime for 16 weeks
    Primary Outcome Measure Information:
    Title
    Mean Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) in Patients With Chronic Asthma
    Description
    Mean percent change from baseline in FEV1 in patients with chronic asthma averaged over 16 weeks for the Beclo and MK+ Beclo groups and averaged over last 10 weeks for the Placebo and MK groups
    Time Frame
    Baseline & over 16 weeks for the Beclomethasone (Beclo) and Montelukast (MK) + Beclo groups and over last 10 weeks for the Placebo and MK groups
    Title
    Mean Change From Baseline in Daytime Symptom Score on the Daytime Asthma Symptoms Diary in Patients With Chronic Asthma
    Description
    The daily daytime symptom score was determined by averaging the daily scores (the patient scored his/her symptoms [from 0 (best) to 6 (worst)] on a daily basis.) for the four questions on the Daytime Asthma Symptoms Diary. The average daytime symptom score for the visit was determined by averaging the daily symptom scores over all days between two consecutive visits.
    Time Frame
    Baseline & over 16 weeks for the Beclo and MK + Beclo groups and over last 10 weeks for the Placebo and MK groups
    Secondary Outcome Measure Information:
    Title
    Mean Percent Change From Baseline in Total Daily Beta-agonist Medication Use
    Description
    Beta-agonist medication use from the daytime and overnight asthma symptoms diaries for each 24-hour period was added to determine the daily total number of puffs used. The average daily number of puffs for the visit was determined as the average daily number of puffs over all days between consecutive visits.
    Time Frame
    Baseline & over 16 weeks for the Beclo and MK + Beclo groups and over last 10 weeks for the Placebo and MK groups
    Title
    Mean Change From Baseline in Morning Peak Flow Rate (PEFR) in Patients With Chronic Asthma
    Description
    Morning PEFR was measured in triplicate immediately upon arising before taking any medication and the best value recorded on the overnight asthma symptoms diary. The mean morning PEFR for the visit was determined by averaging all valid PEFR measurements for the days between consecutive visits.
    Time Frame
    Baseline & over 16 weeks for the Beclo and MK + Beclo groups and over last 10 weeks for the Placebo and MK groups
    Title
    Mean Change From Baseline in Nocturnal Asthma Score on the Overnight Asthma Symptoms Diary in Nocturnal Asthmatic Patients Only
    Description
    Mean change from baseline in Nocturnal asthma score; the patient scored his/her symptoms [from 0 (best) to 3 (worst)] on a daily basis. Responses to the question, "Did you wake up with asthma symptoms?" (no, once, more than once, awake "all night"), were assigned numerical values (0, 1, 2, 3, respectively). The average score for the visit was determined by averaging the daily scores over all days between consecutive visits.
    Time Frame
    Baseline & over 16 weeks for the Beclo and MK + Beclo groups and over last 10 weeks for the Placebo and MK groups

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    15 Years
    Maximum Age & Unit of Time
    85 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Female patients tested negative for pregnancy and agreed to use appropriate contraceptives through out the study Patient was a nonsmoker Patient was in good general health (except for asthma) Exclusion Criteria: Patient was hospitalized Patient was female who was less than 8 weeks postpartum or breast feeding Patient planned to move or vacation away during the study Patient had major surgery within 4 weeks the past 4 weeks Patient has donated blood or participated in a clinical trial within the past 4 weeks Patient was a regular user or recent abuser of alcohol or illicit drugs Patient was 40% over or under normal weight for height
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Medical Monitor
    Organizational Affiliation
    Merck Sharp & Dohme LLC
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    10588598
    Citation
    Laviolette M, Malmstrom K, Lu S, Chervinsky P, Pujet JC, Peszek I, Zhang J, Reiss TF. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med. 1999 Dec;160(6):1862-8. doi: 10.1164/ajrccm.160.6.9803042.
    Results Reference
    result

    Learn more about this trial

    The Clinical Effect of MK0476 With Concomitant Administration of and Removal of Inhaled Beclomethasone in Asthmatic Patients (0476-029)

    We'll reach out to this number within 24 hrs